Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

Recruiting now

Conditions studied: Hematologic Malignancy

In brief

This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.

Key facts

Study ID

NCT05417971

Run by

Northside Hospital, Inc.

People needed

20

Starts

2022-08-29

Expected to finish

2026-12-31

Last updated by the study team

2026-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Availability of 3/6 - 5/6 matched related donor with a negative HLA-cross match in the host vs. graft direction willing to donate peripheral blood stem cells
• KPS >/= 70%
• Hematologic malignancy requiring allogeneic transplantation, with a predicted high risk of relapse following non-myeloablative, low intensity conditioning.

You may not qualify if…

• Poor cardiac function (LVEF <45%)
• Poor pulmonary function (FEV, FVC, DLCO <60%)
• Poor liver function (bilirubin >/= 2.5mg/dL; AST or ALT >3xULN)
• Poor renal function (creatinine clearance <40mL/min)
• HIV-positive; active HepB or HepC
• Uncontrolled infection
• Pregnant female or not able to practice adequate contraception
• Debilitating medical or psychiatric illness which would preclude their giving informed consent

Where it is running

• Caitlin Guzowski — Atlanta, Georgia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.